ALUMIS INC (ALMS) Stock Price, Forecast & Analysis
NASDAQ:ALMS • US0223071020
ALMS Key Statistics, Chart & Performance
The current stock price of ALMS is 29.205 USD. In the past month the price increased by 9.46%. In the past year, price increased by 464.89%.
ALMS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALMS. When comparing the yearly performance of all stocks, ALMS is one of the better performing stocks in the market, outperforming 99.65% of all stocks.
ALMS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALMS. ALMS has a great financial health rating, but its profitability evaluates not so good.
ALMS Financial Highlights
Over the last trailing twelve months ALMS reported a non-GAAP Earnings per Share(EPS) of -4.79. The EPS increased by 42.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.23% | ||
| ROE | -63.71% | ||
| Debt/Equity | 0 |
ALMS Forecast & Estimates
14 analysts have analysed ALMS and the average price target is 36.28 USD. This implies a price increase of 24.23% is expected in the next year compared to the current price of 29.205.
ALMS Ownership
ALMS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.49 | 967.332B | ||
| JNJ | JOHNSON & JOHNSON | 21.19 | 594.88B | ||
| MRK | MERCK & CO. INC. | 22.52 | 302.459B | ||
| PFE | PFIZER INC | 8.94 | 152.718B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.91 | 122.756B | ||
| ZTS | ZOETIS INC | 18.53 | 56.091B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.039B | ||
| VTRS | VIATRIS INC | 6.32 | 18.405B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.33 | 9.385B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALMS
Company Profile
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 233 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Company Info
ALUMIS INC
280 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 233
Phone: 16502316625
ALUMIS INC / ALMS FAQ
Can you describe the business of ALUMIS INC?
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The company is headquartered in South San Francisco, California and currently employs 233 full-time employees. The company went IPO on 2024-06-28. The firm is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
What is the current price of ALMS stock?
The current stock price of ALMS is 29.205 USD. The price increased by 6.16% in the last trading session.
Does ALMS stock pay dividends?
ALMS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALMS stock?
ALMS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists ALMS stock?
ALMS stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for ALUMIS INC?
ALUMIS INC (ALMS) operates in the Health Care sector and the Pharmaceuticals industry.
Is ALUMIS INC (ALMS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALMS.